

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/679,950	10/06/2003	Marcel Hunn	33635/US	3584
7590 08/12/2005		EXAMINER		
David E. Bruhn			SIRMONS, KEVIN C	
Dorsey & Whitney LLP Intellectual Property Department			ART UNIT	PAPER NUMBER
50 South Sixth Street, Suite 1500			3763	
Minneapolis, MN 55402-1498			DATE MAILED: 08/12/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

·		
;	Application No.	Applicant(s)
	10/679,950	HUNN ET AL.
Office Action Summary	Examiner	Art Unit
•	Kevin C. Sirmons	3763
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a - If NO period for reply is specified above, the maximum statutory perions - Failure to reply within the set or extended period for reply will, by state than three months after the may be a part of the may be a served patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a reply be tin reply within the statutory minimum of thirty (30) day od will apply and will expire SIX (6) MONTHS from tute, cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 12	? July 2004.	
,	his action is non-final.	
3) Since this application is in condition for allow closed in accordance with the practice under	wance except for formal matters, pro	
Disposition of Claims		
4) ☐ Claim(s) 1-27 is/are pending in the application 4a) Of the above claim(s) is/are without 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-27 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and	Irawn from consideration.	
Application Papers		
9) The specification is objected to by the Exam 10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to to the Replacement drawing sheet(s) including the cort 11) The oath or declaration is objected to by the	accepted or b) objected to by the he drawing(s) be held in abeyance. Serection is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the papplication from the International Bur * See the attached detailed Office action for a	ents have been received. ents have been received in Applicat riority documents have been receive eau (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s) 1) Motice of References Cited (PTO-892)	4) 🔲 Interview Summary	
2) Notice of Professions State (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/Paper No(s)/Mail Date 7/14/05	Paper No(s)/Mail D	

Application/Control Number: 10/679,950

Art Unit: 3763

DETAILED ACTION

Drawings

The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the transcutaneous perfusion and infusion set or catheter head must be shown or the feature(s) canceled from the claim(s). No new matter should be entered.

Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they include the following reference character(s) not mentioned in the

Application/Control Number: 10/679,950

or in Control Hambor: Toror o

Art Unit: 3763

description: the transcutaneous perfusion and infusion set or catheter head. Corrected drawing sheets in compliance with 37 CFR 1.121(d), or amendment to the specification to add the reference character(s) in the description in compliance with 37 CFR 1.121(b) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

As to claim 1, it is unclear if the at least two materials of differing hardness can include at least one material of variable hardness. The examiner interprets the claims to possibly mean that the at least two materials of differing hardness can include at least

Application/Control Number: 10/679,950

Art Unit: 3763

one material of variable hardness. Therefore, where a claim directed to a device can be read to include the same element twice, the claim is regarded as indefinite.

As to claims 22-25 it is unclear what applicant regards as a transcutaneous infusion/perfusion set.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-27 are rejected under 35 U.S.C. 102(e) as being anticipated by Miller et al U.S. Pat No. 6,887,270.

Miller discloses a cannula comprising a cannula comprising: one of at least one material of variable hardness (col. 7) at least two materials of differing hardness (see entire specification, more preferably (cols. 5-14) and especially preferably (cols. 14-22); as to claim 2, (cols. 5-14, more preferably (cols. 7-14); as to claims 3-6, 9-16(see specification); as to claim 7 and 8, (col. 7); as to claim 17-19, (Miller discloses the same materials, therefore, the material is fully capable of increasing in pliability within in 1 to 5 hours following the beginning of the application); as to claims 20, 21, (figs. 1 and 2); as to claim 22-27, (see entire specification).

Page 5

Application/Control Number: 10/679,950

Art Unit: 3763

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin C. Sirmons whose telephone number is 571-272-4965. The examiner can normally be reached on Monday-Friday 6:30-4:00 ALT FRI.

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kevin C. Sirmons Primary Examiner Art Unit 3763 7/27/05

Kevin C. Sermone